Roche’s Q4 sales increased by 4% at CER (-1% in CHF) to CHF12.6bn, driven by 3% growth at Pharma (CHF9.6bn, -1% in CHF) and 7% at Diagnostics (CHF3bn, flat growth in CHF). For the full year, sales increased by 5% (+1% in CHF) to CHF48.1bn – Pharma +5% (+2% in CHF) and Diagnostics +6% (flat in CHF). The growth was fuelled by the oncology and immunology portfolios, and by the immuno-diagnostics business within professional diagnostics (+8%). These numbers were slightly ahead of our
17 Feb 2016
Robust top-line pulled down by substantial one-offs and investments
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Robust top-line pulled down by substantial one-offs and investments
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
17 Feb 2016 -
Author:
Kamla Singh -
Pages:
3
Roche’s Q4 sales increased by 4% at CER (-1% in CHF) to CHF12.6bn, driven by 3% growth at Pharma (CHF9.6bn, -1% in CHF) and 7% at Diagnostics (CHF3bn, flat growth in CHF). For the full year, sales increased by 5% (+1% in CHF) to CHF48.1bn – Pharma +5% (+2% in CHF) and Diagnostics +6% (flat in CHF). The growth was fuelled by the oncology and immunology portfolios, and by the immuno-diagnostics business within professional diagnostics (+8%). These numbers were slightly ahead of our